Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Hata

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Clinical Genitourinary Cancer|April 21, 2024
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate CancerKojiro Tashiro, Shoji Kimura, Shunsuke Tsuzuki, et al.
The Prostate|September 24, 2021
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancerTakafumi Yanagisawa, Takahiro Kimura, Keiichiro Mori, et al.
The Prostate|January 20, 2023
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapyTakafumi Yanagisawa, Kenichi Hata, Shintaro Narita, et al.
Prostate International|April 11, 2025
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, et al.
International Journal of Clinical Oncology|June 24, 2022
Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxelShintaro Narita, Takahiro Kimura, Shingo Hatakeyama, et al.
World Journal of Urology|May 21, 2022
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysisTakafumi Yanagisawa, Takahiro Kimura, Kenichi Hata, et al.
World Journal of Urology|February 26, 2022
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapyShintaro Narita, Takahiro Kimura, Shingo Hatakeyama, et al.
Japanese Journal of Clinical Oncology|October 19, 2024
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative studyShuhei Hara, Fumihiko Urabe, Kojiro Tashiro, et al.
Japanese Journal of Clinical Oncology|July 23, 2021
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancerShunsuke Tsuzuki, Shota Kawano, Wataru Fukuokaya, et al.
Japanese Journal of Clinical Oncology|July 22, 2024
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Yu Imai, Yuma Goto, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Clinical Genitourinary Cancer|April 21, 2024
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate CancerKojiro Tashiro, Shoji Kimura, Shunsuke Tsuzuki, et al.
The Prostate|September 24, 2021
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancerTakafumi Yanagisawa, Takahiro Kimura, Keiichiro Mori, et al.
The Prostate|January 20, 2023
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapyTakafumi Yanagisawa, Kenichi Hata, Shintaro Narita, et al.
Prostate International|April 11, 2025
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, et al.
International Journal of Clinical Oncology|June 24, 2022
Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxelShintaro Narita, Takahiro Kimura, Shingo Hatakeyama, et al.
World Journal of Urology|May 21, 2022
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysisTakafumi Yanagisawa, Takahiro Kimura, Kenichi Hata, et al.
World Journal of Urology|February 26, 2022
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapyShintaro Narita, Takahiro Kimura, Shingo Hatakeyama, et al.
Japanese Journal of Clinical Oncology|October 19, 2024
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative studyShuhei Hara, Fumihiko Urabe, Kojiro Tashiro, et al.
Japanese Journal of Clinical Oncology|July 23, 2021
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancerShunsuke Tsuzuki, Shota Kawano, Wataru Fukuokaya, et al.
Japanese Journal of Clinical Oncology|July 22, 2024
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Yu Imai, Yuma Goto, et al.
Pageof 5